Skip to content

Jianjun Yang

7 papers in the library · 436 citations · publishing 2017-2025

Papers

Sort Most recent Most cited

MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions

Psychedelics. October 14, 2025 Mingming Zhao, Jianjun Yang, Kenji Hashimoto

MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory...

Repeated intermittent administration of 3,4-methylenedioxymethamphetamine mitigates demyelination in the brain from cuprizone-treated mice.

European Journal of Pharmacology March 15, 2025 Mingming Zhao, Akifumi Eguchi, Rumi Murayama et al. 6 citations

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as a recreational drug, may also offer therapeutic benefits for mental health. Population-based studies suggest that MDMA users have a lower risk of demyelinating diseases, such as depression. Given the role of the gut microbiota in mediating MDMA's effects, we hypothesized that MDMA might confer mental health benefits via the gut-brain...

Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions

Journal of Anesthesia and Translational Medicine July 11, 2024 Kenji Hashimoto, Mingming Zhao, Tingting Zhu et al. 32 citations

Ketamine, a dissociative anesthetic, is widely utilized in both human and veterinary anesthesia. Its (S)-enantiomer, esketamine, is similarly employed for anesthesia and analgesia. The anesthetic effects of both ketamine and esketamine arise from their antagonism of the N-methyl-D-aspartate receptor (NMDAR). In field of psychiatry, the rapid-acting antidepressant properties of ketamine for...

(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression.

Neuroscience and Biobehavioral Reviews June 1, 2022 Xingming Wang, Jianjun Yang, Kenji Hashimoto

Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. The increasing social and economic burdens of neurological disorders are driven by global population growth and aging. Depression is a common psychiatric symptom in numerous neurological disorders. It is also a risk factor for Alzheimer's disease (AD) and other dementias, Parkinson's...

Iron overload contributes to general anaesthesia-induced neurotoxicity and cognitive deficits

Journal of Neuroinflammation April 10, 2020 Jing Wu, Jianjun Yang, Yan Cao et al. 140 citations

Abstract Background Increasing evidence suggests that multiple or long-time exposure to general anaesthesia (GA) could be detrimental to cognitive development in young subjects and might also contribute to accelerated neurodegeneration in the elderly. Iron is essential for normal neuronal function, and excess iron in the brain is implicated in several neurodegenerative diseases. However, the...

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Translational Psychiatry November 7, 2019 Chun Yang, Jianjun Yang, A. Luo et al. 189 citations

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are...

Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine

Scientific Reports June 5, 2017 Ze-Min Xie, Xingming Wang, Ning Xu et al. 69 citations

Although pain is frequently accompanied with depression, little is known about the risk factors contributing to individual differences to the comorbidity of pain and depression. In this study, we examined whether cytokines and brain-derived neurotrophic factor (BDNF) might contribute to the individual differences in the development of neuropathic pain-induced depression. Rats were randomly...